Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomised controlled trial

Lancet

Volumn 360, Issue 9337, 2002, Pages 895-900

  Ghofrani, Hossein Ardeschir ^a   Wiedemann, Ralph ^a   Rose, Frank ^a   Schermuly, Ralph T ^a   Olschewski, Horst ^a   Weissmann, Norbert ^a   Gunther, Andreas ^a   Walmrath, Dieter ^a   Seeger, Werner ^a   Grimminger, Friedrich ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL;

ADULT; AGED; ARTERIAL OXYGEN SATURATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN; INHALATION; LUNG ARTERY PRESSURE; LUNG FIBROSIS; LUNG VASCULAR RESISTANCE; LUNG VENTILATION PERFUSION RATIO; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE; VASODILATATION;

EID: 0037152092     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11024-5     Document Type: Article

References (26)

1. King T.E. Jr, Tooze J.A., Schwarz M.I., Brown K.R., Cherniack R.M. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 164:2001;1171-1181.
2. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 334:1996;296-302.
3. Egan J.J. New treatments for pulmonary fibrosis? Lancet. 354:1999;1839-1840.
4. Agusti A.G., Rodriguez-Roisin R. Effect of pulmonary hypertension on gas exchange. Eur Respir J. 6:1993;1371-1377.
5. Olschewski H., Ghofrani H.A., Walmrath D., et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med. 160:1999;600-607.
6. Rossaint R., Falke K.J., Lopez F., Slama K., Pison U., Zapol W.M. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 328:1993;399-405.
7. Walmrath D., Schneider T., Pilch J., Grimminger F., Seeger W. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet. 342:1993;961-962.
8. Olschewski H., Walmrath D., Schermuly R., Ghofrani A., Grimminger F., Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med. 124:1996;820-824.
9. Olschewski H., Ghofrani H.A., Schmehl T., et al. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. Ann Intern Med. 132:2000;435-443.
10. Hoeper M.M., Schwarze M., Ehlerding S., et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 342:2000;1866-1870.
11. Channick R.N., Newhart J.W., Johnson F.W., et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest. 109:1996;1545-1549.
12. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment - international consensus statement. Am J Respir Crit Care Med. 161:2000;646-664.
13. Wagner P.D. Calculating the distribution of ventilation-perfusion ratios from inert gas elimination data. Fed Proc. 41:1982;136-139.
14. Walmrath D., Schneider T., Pilch J., Schermuly R., Grimminger F., Seeger W. Effects of aerosolized prostacyclin in severe pneumonia: impact of fibrosis. Am J Respir Crit Care Med. 151:1995;724-730.
15. Schermuly R.T., Gunther A., Ermert M., et al. Conebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation. Am J Physiol Lung Cell Mol Physiol. 280:2001;L792-L800.
16. Hoeper M.M., Olschewski H., Ghofrani H.A., et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol. 35:2000;176-182.
17. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 75:1995;725-748.
18. Ahn H.S., Foster M., Cable M., Pitts B.J., Sybertz E.J. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol. 308:1991;191-197.
19. Rabe K.F., Tenor H., Dent G., Schudt C., Nakashima M., Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol. 266:1994;L536-L543.
20. Wilkens H., Guth A., Konig J., et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 104:2001;1218-1222.
21. Ghofrani H.A., Wiedemann R., Rose F., et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 136:2002;515-522.
22. Wiedemann R., Ghofrani H.A., Weissmann N., et al. Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: response to iloprost inhalation. J Am Coll Cardiol. 38:2001;1130-1136.
23. Weimann J., Ullrich R., Hromi J., et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology. 92:2000;1702-1712.
24. Grimminger F., Spriestersbach R., Weissmann N., Walmrath D., Seeger W. Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs. J Appl Physiol. 78:1995;1509-1515.
25. Weissmann N., Winterhalder S., Nollen M., et al. NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. Am J Physiol Lung Cell Mol Physiol. 280:2001;L638-L645.
26. Ide H., Nakano H., Ogasa T., Osanai S., Kikuchi K., Iwamoto J. Regulation of pulmonary circulation by alveolar oxygen tension via airway nitric oxide. J Appl Physiol. 87:1999;1629-1636.